SCSI: The Stem Cell Stock Index is the leading source for unbiased actionable data, analysis, and insight regarding the U.S. stem cell therapeutics industry, its publicly traded companies, their clinical trials, and the news that moves the market.

Recent Clinical Trials Updates

(There were no trial updates in the past month. Please check back soon.)
The New Clinical Trials Dataviewer

An interactive visual interface to our database of 196 commercially sponsored stem cell clinical trials, worldwide, from 1998 to today

The Latest Organelles Essays

ATHX: Is 2013 the Beginning of the End For Stem Cells?
Oct 12, 2013
This is shaping up to be both the best of years and the worst of years for U.S. stem cell therapeutic companies, with pioneering efforts finally running out of steam or throwing in the towel even as new initiatives rise up to take their places
FATE: A First Look at Fate Therapeutics
Oct 3, 2013
A fresh idea for the stem cell therapeutics industry, but not without fresh risks.
CAPR: The New Kid In Town: A First Look at Capricor Inc.'s Business Fundamentals
Sep 30, 2013
Can Capricor's proposed reverse merger see its cardiac stem cell product across the finish line?
Fifteen Years, 60 Companies, 196 Trials (A Continuing Series)
Sep 7, 2013
A quantitative analysis of U.S.-registered commercial stem cell clinical trials: Where we've been, and where we're going.
Part I: Introduction
Part II: Cell Types & Indications (Cardiovascular)
Part III: Cell Types & Indications (CNS)
Part IV: Database Viewer
Appendix A: Cell Type Nomenclature
KOOL: Caveat Emptor, or Cave Canem?
Aug 9, 2013
Reputable stem cell companies build value by striving to deliver lifesaving therapies to the clinic, while some others just pump out press releases.

Current Happenings

Feb 19, 2014
Another losing quarter for this rejiggered company with big plans.
Feb 13, 2014
Combined company to be renamed Cesca Therapeutics
Jan 22, 2014
With the anticipated results already priced in, shares moved little on the news.
Jan 22, 2014
'October Surprise' as shareholders vote on merger with purveyor of Indian stem cell treatments.
Jan 22, 2014
Arguably the worst-performing stem cell company will seek a new leader.
Jan 18, 2014
In ongoing proxy vote, the company won't take 'no' for an answer.
Jan 7, 2014
The company's neural stem cell trials earn their second downgrade in 2 months.
Jan 6, 2014
Continues the wind-down of its stem cell programs promised last year.